Business Summary for FLMLY.
Flamel Technologies S.A. is a drug delivery company engaged in the
development and commercialization of controlled-release therapeutic products
based on its proprietary polymer-based technology. For the fiscal year ended
12/31/98, revenues rose 18% to $9.5 million. Net loss rose 14% to $7.8
million. Revenues reflect the increased research payments from the Company's
various partners. Higher loss reflects costs of the Venissieux pilot plant.
Recent Earnings Announcement
For the 3 months ended 03/31/1999, revenues were 1,298; after tax earnings
were -2,877. (Preliminary; reported in thousands of dollars.)
Price and Volume
(updated Dec 9, 1999)
52-Week Low
$1.00
Recent Price
$2.625
52-Week High
$4.875
Beta
1.10
Daily Volume
(3-month avg)
39.3K
Share-Related Items
Market Capitalization
$34.0M
Shares Outstanding
12.9M
Float
4.40M
Tom B. |
